share_log

四環醫藥:截至二零二三年十二月三十一日止之股份發行人的證券變動月報表

SIHUAN PHARM: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2023

香港交易所 ·  Jan 3 03:00
Summary by Moomoo AI
四環醫藥(SIHUAN PHARM)於2024年1月3日向香港交易及結算所有限公司提交了截至2023年12月31日的證券變動月報表。報告顯示,公司的法定/註冊股本及已發行股份在該月份均無變動,維持在1,000,000,000港元及9,329,999,206股。此外,根據2017年10月24日採納的股份期權計劃,公司本月底結存的股份期權數目為74,110,000股,並無新增發行。四環醫藥確認所有證券發行均已獲董事會批准,並符合香港聯合交易所有限公司證券上市規則的相關要求。
四環醫藥(SIHUAN PHARM)於2024年1月3日向香港交易及結算所有限公司提交了截至2023年12月31日的證券變動月報表。報告顯示,公司的法定/註冊股本及已發行股份在該月份均無變動,維持在1,000,000,000港元及9,329,999,206股。此外,根據2017年10月24日採納的股份期權計劃,公司本月底結存的股份期權數目為74,110,000股,並無新增發行。四環醫藥確認所有證券發行均已獲董事會批准,並符合香港聯合交易所有限公司證券上市規則的相關要求。
SIHUAN PHARM FILED WITH HONG KONG TRADING AND SETTLEMENT LIMITED ON 3 JANUARY 2024 WITH THE SECURITIES MONTHLY CHANGE REPORT FOR THE YEAR ENDED 31 DECEMBER 2023. The report showed that the company's regulated/registered share capital and issued shares remained unchanged during the month, at HK$1,000,000,000 and 9,329,999,206 shares. In addition, under the share option plan adopted on October 24, 2017, the Company had 74,110,000 shares outstanding at the end of this month, with no additional issuance. Four Circle Pharmaceuticals confirms that all securities issues have been approved by the Board of Directors and comply with the relevant requirements of the Securities Listing Rules of the Hong Kong Stock Exchange Limited.
SIHUAN PHARM FILED WITH HONG KONG TRADING AND SETTLEMENT LIMITED ON 3 JANUARY 2024 WITH THE SECURITIES MONTHLY CHANGE REPORT FOR THE YEAR ENDED 31 DECEMBER 2023. The report showed that the company's regulated/registered share capital and issued shares remained unchanged during the month, at HK$1,000,000,000 and 9,329,999,206 shares. In addition, under the share option plan adopted on October 24, 2017, the Company had 74,110,000 shares outstanding at the end of this month, with no additional issuance. Four Circle Pharmaceuticals confirms that all securities issues have been approved by the Board of Directors and comply with the relevant requirements of the Securities Listing Rules of the Hong Kong Stock Exchange Limited.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more